Bryan Roberts

Bryan earned a PhD in chemistry and chemical biology from Harvard and an AB degree from Dartmouth College, Phi Beta Kappa, also in chemistry. 

​

Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has ranked on Forbes' Midas List twelve times, 2008 - 2020. In 2019, the National Venture Capital Association presented him with the Excellence in Healthcare Innovation Award.

Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Palo Alto and invests broadly across the healthcare industry. Bryan is currently involved with numerous public and private companies including 10X Genomics, Castlight Health, Devoted Health, Doctor on Demand, Encoded Therapeutics, Grand Rounds, Inscripta and Lyra Health. Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), Ikaria (acquired by Mallinckrodt), Illumina (NASDAQ: ILMN), Ironwood Pharmaceuticals (NASDAQ: IRWD), Sirna Therapeutics (acquired by Merck), and Zeltiq (acquired by Allergan).

Bryan is a member of Kauffman Fellows Class 3 and served his fellowship under mentor Anthony Evnin at Venrock in New York.